HALOZYME THERAPEUTICS, INC. ·

HALO 8-K 2026-09-22

HALOZYME THERAPEUTICS, INC. (HALO) 8-K dated 2026-09-22 — accession 0001193125-26-398015. This URL is the filing, not the HALO hub.

HALOZYME THERAPEUTICS, INC. (HALO) is a biotechnology company listed on US.

HALOZYME THERAPEUTICS, INC. filed a 8-K on 2026-09-22. Accession 0001193125-26-398015.

Cached items: 1.01, 2.03, 3.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B and trailing P/E 33.4.

Not investment advice. The HALO SEC hub lists recent forms. The stock page is the research view.

Source on EDGAR

Lician Pro $19.99/mo or $149/yr